vs
Sprinklr, Inc.（CXM）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Sprinklr, Inc.的1.0倍（$219.9M vs $219.1M），Sprinklr, Inc.净利率更高（1.3% vs -1.0%，领先2.3%），Sprinklr, Inc.同比增速更快（9.2% vs 2.0%），Sprinklr, Inc.自由现金流更多（$19.8M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 6.2%）
Sprinklr是美国的一家SaaS企业，专注于客户体验管理（CXM）平台研发。其同名产品整合了社媒营销、社交广告、内容管理、团队协作、员工倡导、客户服务、社媒调研与监测等多类应用模块，为企业提供全链路的客户体验管理解决方案。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CXM vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$219.1M
营收增速更快
CXM
高出7.2%
2.0%
净利率更高
CXM
高出2.3%
-1.0%
自由现金流更多
CXM
多$3.0M
$16.8M
两年增速更快
OFIX
近两年复合增速
6.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.1M | $219.9M |
| 净利润 | $2.9M | $-2.2M |
| 毛利率 | 66.4% | 71.1% |
| 营业利润率 | 5.3% | 0.2% |
| 净利率 | 1.3% | -1.0% |
| 营收同比 | 9.2% | 2.0% |
| 净利润同比 | -72.2% | 92.4% |
| 每股收益（稀释后） | $0.01 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXMOFIX
| Q4 25 | $219.1M | $219.9M | ||
| Q3 25 | $212.0M | $205.6M | ||
| Q2 25 | $205.5M | $203.1M | ||
| Q1 25 | $202.5M | $193.6M | ||
| Q4 24 | $200.7M | $215.7M | ||
| Q3 24 | $197.2M | $196.6M | ||
| Q2 24 | $196.0M | $198.6M | ||
| Q1 24 | $194.2M | $188.6M |
净利润CXMOFIX
| Q4 25 | $2.9M | $-2.2M | ||
| Q3 25 | $12.6M | $-22.8M | ||
| Q2 25 | $-1.6M | $-14.1M | ||
| Q1 25 | $98.7M | $-53.1M | ||
| Q4 24 | $10.5M | $-29.1M | ||
| Q3 24 | $1.8M | $-27.4M | ||
| Q2 24 | $10.6M | $-33.4M | ||
| Q1 24 | $21.1M | $-36.0M |
毛利率CXMOFIX
| Q4 25 | 66.4% | 71.1% | ||
| Q3 25 | 68.2% | 72.2% | ||
| Q2 25 | 69.5% | 68.7% | ||
| Q1 25 | 71.0% | 62.8% | ||
| Q4 24 | 71.2% | 69.0% | ||
| Q3 24 | 72.6% | 68.7% | ||
| Q2 24 | 73.9% | 67.8% | ||
| Q1 24 | 75.5% | 67.5% |
营业利润率CXMOFIX
| Q4 25 | 5.3% | 0.2% | ||
| Q3 25 | 7.7% | -8.3% | ||
| Q2 25 | -0.9% | -7.9% | ||
| Q1 25 | 5.2% | -25.2% | ||
| Q4 24 | 3.9% | -5.3% | ||
| Q3 24 | -0.0% | -9.6% | ||
| Q2 24 | 2.9% | -12.5% | ||
| Q1 24 | 9.5% | -15.6% |
净利率CXMOFIX
| Q4 25 | 1.3% | -1.0% | ||
| Q3 25 | 5.9% | -11.1% | ||
| Q2 25 | -0.8% | -6.9% | ||
| Q1 25 | 48.7% | -27.4% | ||
| Q4 24 | 5.2% | -13.5% | ||
| Q3 24 | 0.9% | -13.9% | ||
| Q2 24 | 5.4% | -16.8% | ||
| Q1 24 | 10.9% | -19.1% |
每股收益（稀释后）CXMOFIX
| Q4 25 | $0.01 | $-0.05 | ||
| Q3 25 | $0.05 | $-0.57 | ||
| Q2 25 | $-0.01 | $-0.36 | ||
| Q1 25 | $0.35 | $-1.35 | ||
| Q4 24 | $0.04 | $-0.76 | ||
| Q3 24 | $0.01 | $-0.71 | ||
| Q2 24 | $0.04 | $-0.88 | ||
| Q1 24 | $0.07 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $558.1M | $450.0M |
| 总资产 | $1.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CXMOFIX
| Q4 25 | $189.6M | $82.0M | ||
| Q3 25 | $125.4M | $62.9M | ||
| Q2 25 | $126.4M | $65.6M | ||
| Q1 25 | $145.3M | $58.0M | ||
| Q4 24 | $93.2M | $83.2M | ||
| Q3 24 | $119.1M | $30.1M | ||
| Q2 24 | $126.8M | $26.4M | ||
| Q1 24 | $164.0M | $27.0M |
总债务CXMOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CXMOFIX
| Q4 25 | $558.1M | $450.0M | ||
| Q3 25 | $543.4M | $442.5M | ||
| Q2 25 | $639.8M | $458.3M | ||
| Q1 25 | $612.1M | $458.3M | ||
| Q4 24 | $497.0M | $503.1M | ||
| Q3 24 | $469.0M | $525.9M | ||
| Q2 24 | $610.9M | $546.0M | ||
| Q1 24 | $679.7M | $570.3M |
总资产CXMOFIX
| Q4 25 | $1.1B | $850.6M | ||
| Q3 25 | $1.1B | $832.6M | ||
| Q2 25 | $1.2B | $837.2M | ||
| Q1 25 | $1.2B | $823.1M | ||
| Q4 24 | $970.3M | $893.3M | ||
| Q3 24 | $983.8M | $867.9M | ||
| Q2 24 | $1.1B | $882.0M | ||
| Q1 24 | $1.2B | $906.0M |
负债/权益比CXMOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 9.0% | 7.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 6.87× | — |
| 过去12个月自由现金流最近4个季度 | $142.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CXMOFIX
| Q4 25 | $20.0M | $27.7M | ||
| Q3 25 | $34.8M | $12.4M | ||
| Q2 25 | $83.8M | $11.6M | ||
| Q1 25 | $5.4M | $-18.4M | ||
| Q4 24 | $9.2M | $23.7M | ||
| Q3 24 | $21.3M | $11.7M | ||
| Q2 24 | $41.7M | $9.0M | ||
| Q1 24 | $17.3M | $-18.6M |
自由现金流CXMOFIX
| Q4 25 | $19.8M | $16.8M | ||
| Q3 25 | $34.4M | $2.5M | ||
| Q2 25 | $83.5M | $4.5M | ||
| Q1 25 | $4.6M | $-25.1M | ||
| Q4 24 | $8.2M | $15.2M | ||
| Q3 24 | $19.8M | $6.3M | ||
| Q2 24 | $39.2M | $-360.0K | ||
| Q1 24 | $15.2M | $-29.1M |
自由现金流率CXMOFIX
| Q4 25 | 9.0% | 7.6% | ||
| Q3 25 | 16.2% | 1.2% | ||
| Q2 25 | 40.6% | 2.2% | ||
| Q1 25 | 2.3% | -13.0% | ||
| Q4 24 | 4.1% | 7.0% | ||
| Q3 24 | 10.1% | 3.2% | ||
| Q2 24 | 20.0% | -0.2% | ||
| Q1 24 | 7.9% | -15.4% |
资本支出强度CXMOFIX
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 0.2% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.4% | 3.5% | ||
| Q4 24 | 0.5% | 4.0% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 1.3% | 4.7% | ||
| Q1 24 | 1.1% | 5.6% |
现金转化率CXMOFIX
| Q4 25 | 6.87× | — | ||
| Q3 25 | 2.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 11.58× | — | ||
| Q2 24 | 3.92× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
